PL2121898T3 - Sposób konserwowania cząstek wirusowych - Google Patents

Sposób konserwowania cząstek wirusowych

Info

Publication number
PL2121898T3
PL2121898T3 PL08718824T PL08718824T PL2121898T3 PL 2121898 T3 PL2121898 T3 PL 2121898T3 PL 08718824 T PL08718824 T PL 08718824T PL 08718824 T PL08718824 T PL 08718824T PL 2121898 T3 PL2121898 T3 PL 2121898T3
Authority
PL
Poland
Prior art keywords
viral particles
polyethyleneimine
preserving
concentration
preserving viral
Prior art date
Application number
PL08718824T
Other languages
English (en)
Polish (pl)
Inventor
Jeffrey Drew
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Publication of PL2121898T3 publication Critical patent/PL2121898T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Jellies, Jams, And Syrups (AREA)
PL08718824T 2007-03-19 2008-03-19 Sposób konserwowania cząstek wirusowych PL2121898T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0705245.9A GB0705245D0 (en) 2007-03-19 2007-03-19 Stable biological products
US91722007P 2007-05-10 2007-05-10
PCT/GB2008/000987 WO2008114021A1 (en) 2007-03-19 2008-03-19 Method for preserving viral particles
EP08718824A EP2121898B8 (en) 2007-03-19 2008-03-19 Method for preserving viral particles

Publications (1)

Publication Number Publication Date
PL2121898T3 true PL2121898T3 (pl) 2012-02-29

Family

ID=38008686

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08718824T PL2121898T3 (pl) 2007-03-19 2008-03-19 Sposób konserwowania cząstek wirusowych

Country Status (18)

Country Link
US (1) US8313897B2 (enExample)
EP (1) EP2121898B8 (enExample)
JP (1) JP2010521961A (enExample)
KR (1) KR20100015613A (enExample)
CN (1) CN101636486A (enExample)
AT (1) ATE525455T1 (enExample)
AU (1) AU2008228086A1 (enExample)
BR (1) BRPI0808960A2 (enExample)
CA (1) CA2681182A1 (enExample)
DK (1) DK2121898T3 (enExample)
ES (1) ES2370675T3 (enExample)
GB (2) GB0705245D0 (enExample)
HR (1) HRP20110814T1 (enExample)
IL (1) IL200671A0 (enExample)
PL (1) PL2121898T3 (enExample)
RU (1) RU2009138344A (enExample)
SI (1) SI2121898T1 (enExample)
WO (1) WO2008114021A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214464B2 (ja) 2005-12-28 2013-06-19 アドバンスド バイオニュートリション コーポレーション 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
GB2479069B (en) 2008-09-24 2012-07-25 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
AU2010254235B2 (en) 2009-05-26 2015-04-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CA2785815C (en) * 2010-01-28 2018-04-24 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
AU2011234264B2 (en) * 2010-03-31 2016-02-04 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
US10206960B2 (en) * 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
HUE042330T2 (hu) 2010-03-31 2019-06-28 Stabilitech Biopharma Ltd Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására
ES2676656T3 (es) 2010-08-13 2018-07-23 Advanced Bionutrition Corp. Composición estabilizante de almacenamiento en seco para materiales biológicos
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR102685914B1 (ko) 2015-07-29 2024-07-16 어드밴스드 바이오뉴트리션 코프. 특수 식이 용도를 위한 안정한 프로바이오틱 건조 조성물
WO2017035664A1 (en) 2015-09-02 2017-03-09 Mcmaster University Enhanced thermal stability for adenoviral vectors through spray drying
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US11626228B2 (en) * 2016-12-22 2023-04-11 Rogers Corporation Multi-layer magneto-dielectric material
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
KR102684237B1 (ko) 2017-06-21 2024-07-11 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
AU2019345595A1 (en) * 2018-09-28 2021-04-15 Otsuka Pharmaceutical Factory,Inc. Mammal cell preserving solution containing acarbose or stachyose
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR CANCER THERAPY
IL284421B2 (en) 2018-12-28 2025-05-01 Transgene M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
JP2023521803A (ja) * 2020-04-14 2023-05-25 スペクトラム・ソリューションズ・エルエルシー ウイルス核酸の検出用製品及びその検出方法
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
IL304904A (en) 2021-02-01 2023-10-01 St Phi Therapeutics Co Ltd Target protein degradation system and its use
WO2022246323A1 (en) * 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN113655057A (zh) * 2021-08-24 2021-11-16 威世药业（如皋）有限公司 一种检测冷冻干燥处理对痘苗病毒毒力影响的设备
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312233A1 (en) 1997-11-26 1999-06-03 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
CA2494241C (en) 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20040110267A1 (en) * 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법

Also Published As

Publication number Publication date
IL200671A0 (en) 2011-08-01
EP2121898B8 (en) 2012-02-15
WO2008114021A1 (en) 2008-09-25
ES2370675T3 (es) 2011-12-21
JP2010521961A (ja) 2010-07-01
GB0705245D0 (en) 2007-04-25
DK2121898T3 (da) 2012-01-09
CN101636486A (zh) 2010-01-27
SI2121898T1 (sl) 2012-02-29
GB2459611A (en) 2009-11-04
EP2121898A1 (en) 2009-11-25
GB2459611B (en) 2011-02-16
AU2008228086A1 (en) 2008-09-25
GB0915291D0 (en) 2009-10-07
KR20100015613A (ko) 2010-02-12
ATE525455T1 (de) 2011-10-15
RU2009138344A (ru) 2011-04-27
CA2681182A1 (en) 2008-09-25
US8313897B2 (en) 2012-11-20
EP2121898B1 (en) 2011-09-21
HRP20110814T1 (hr) 2012-01-31
BRPI0808960A2 (pt) 2014-08-26
US20100015177A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
GB2459611B (en) Method for preserving viral particles
GB2479069A (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
WO2006070370A3 (en) Stem cells culture systems
WO2009007852A3 (en) Multipotent/pluripotent cells and methods
WO2009118253A3 (en) Hair styling composition
WO2008019871A3 (de) Neue salze des wirkstoffs rasagilin
TW200700092A (en) Tigecycline compositions and methods of preparation
WO2011091420A3 (en) Osteogenic cell delivery matrix
WO2006116622A3 (en) Novel methods and devices for evaluating poisons
NO20080158L (no) Oyedraper som inneholder roflumilast
MX2014007643A (es) Edulcorante natural y metodo para elaborarlo.
WO2007109600A3 (en) Extractions and methods comprising elder species
BRPI0923357A2 (pt) Métodos para acelerar o crescimento de raízes em uma planta, e para melhorar a absorção foliar de um composto biologicamente ativo por uma planta.
WO2011115809A3 (en) High energy radiation insensitive analyte sensors
WO2010059433A3 (en) Mems pressure and acceleration dosimeter
WO2007050462A3 (en) Method of treating silica and inkjet recording material
Ni et al. The self-force and effective mass of a generally accelerating dislocation I: Screw dislocation
WO2007046890A8 (en) Lozenge for treatment of dry mouth and related conditions
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
HK1159119B (en) Method for preserving polypeptides using a sugar and polyethyleneimine
WO2011062559A8 (en) Methods of enhancing pluripotentcy
WO2010062136A3 (ko) 미토콘드리아 활성화를 위한 조성물
WO2009051016A1 (ja) シリコン量子ドット、及びそれを用いた生体物質標識剤
WO2007019499A3 (en) Nucleic acid sequences associated with cell states